{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:24:13Z","timestamp":1775183053485,"version":"3.50.1"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008659","name":"European Committee for Treatment and Research in Multiple Sclerosis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.msard.2021.103418","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T17:17:04Z","timestamp":1637601424000},"page":"103418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Derisking CD20-therapies for long-term use"],"prefix":"10.1016","volume":"57","author":[{"given":"Ide","family":"Smets","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103418_bib0069","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3899\/jrheum.130526","article-title":"Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab","volume":"41","author":"Abdulkader","year":"2014","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.msard.2021.103418_bib0083","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.103418_bib0065","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/ced.13726","article-title":"Early-onset neutropenia after rituximab therapy for bullous pemphigoid","volume":"44","author":"Adler","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.msard.2021.103418_bib0086","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.vaccine.2010.12.072","article-title":"The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab","volume":"29","author":"Arad","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.msard.2021.103418_bib0064","first-page":"1","article-title":"Early-onset neutropenia induced by rituximab in a patient with lupus nephritis and hemolytic anemia","volume":"2015","author":"Arroyo-\u00c1vila","year":"2015","journal-title":"Case Rep. Rheumatol."},{"key":"10.1016\/j.msard.2021.103418_bib0012","doi-asserted-by":"crossref","first-page":"e977","DOI":"10.1212\/NXI.0000000000000977","article-title":"Rituximab-induced hypogammaglobulinemia and infections in AQP4 and MOG antibody\u2013associated diseases","volume":"8","author":"Avouac","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103418_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102279","article-title":"The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis","volume":"44","author":"Baker","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103418_bib0091","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103418_bib0082","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103418_bib0070","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/qjmed\/hcs015","article-title":"Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center","volume":"105","author":"Besada","year":"2012","journal-title":"QJM"},{"key":"10.1016\/j.msard.2021.103418_bib0078","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.msard.2021.103418_bib0087","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.93222","article-title":"Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab","volume":"2","author":"Cho","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.msard.2021.103418_bib0051","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to the development of hypogammaglobulinemia and infections post-rituximab","volume":"36","author":"Christou","year":"2017","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.msard.2021.103418_bib0027","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3389\/fimmu.2014.00626","article-title":"Immunoglobulin replacement therapy in secondary hypogammaglobulinemia","volume":"5","author":"Compagno","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2021.103418_bib0050","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.msard.2018.11.027","article-title":"Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol","volume":"27","author":"Conte","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103418_bib0063","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2010-01-254417","article-title":"How I treat common variable immune deficiency","volume":"116","author":"Cunningham-Rundles","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.msard.2021.103418_bib0016","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1158\/1078-0432.CCR-16-2026","article-title":"Alterations in the immune cell composition in premalignant breast tissue that precede breast cancer development","volume":"23","author":"Degnim","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.msard.2021.103418_bib0010","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.clinph.2019.12.042","article-title":"P36 serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions","volume":"131","author":"Derfuss","year":"2020","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.msard.2021.103418_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000991","article-title":"Vaccine hesitancy in patients with multiple sclerosis: preparing for the SARS-CoV-2 vaccination challenge","volume":"8","author":"Diem","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103418_bib0042","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/WCO.0000000000000922","article-title":"Use of disease-modifying drugs during pregnancy and breastfeeding","volume":"34","author":"Dobson","year":"2021","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2021.103418_bib0043","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/practneurol-2018-002060","article-title":"UK consensus on pregnancy in multiple sclerosis: \u2018Association of British Neurologists\u2019 guidelines","volume":"19","author":"Dobson","year":"2019","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.msard.2021.103418_bib0077","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1177\/1352458517720044","article-title":"Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies","volume":"24","author":"Dunn","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.103418_bib0057","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.idc.2017.07.017","article-title":"Influence of aging and environment on presentation of infection in older adults","volume":"31","author":"El Chakhtoura","year":"2017","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.msard.2021.103418_bib0006","unstructured":"EMA. Summary of product characteristics rituximab, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mabthera-epar-product-information_en.pdf (accessed 7 July 2021)."},{"key":"10.1016\/j.msard.2021.103418_bib0007","unstructured":"EMA. Summary of product characteristics ocrelizumab, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf (accessed 7 July 2021)."},{"key":"10.1016\/j.msard.2021.103418_bib0008","unstructured":"EMA. Summary of product characteristics ofatumumab, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kesimpta-epar-product-information_en.pdf (accessed 7 July 2021)."},{"key":"10.1016\/j.msard.2021.103418_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofy174","article-title":"Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management","volume":"5","author":"Epstein","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.msard.2021.103418_bib0021","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1212\/WNL.0000000000008157","article-title":"Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology","volume":"93","author":"Farez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103418_bib0024","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pvr.2017.06.002","article-title":"HPV vaccination of immunocompromised hosts","volume":"4","author":"Garland","year":"2017","journal-title":"Papillomavirus Res."},{"key":"10.1016\/j.msard.2021.103418_bib0094","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286420915005","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years\u2019 follow-up of DEFINE, CONFIRM, and ENDORSE","volume":"13","author":"Gold","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.103418_bib0028","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.msard.2021.103418_bib0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25119","article-title":"B-cell therapy for multiple sclerosis: entering an era","volume":"83","author":"Greenfield","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103418_bib0004","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103418_bib0076","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103418_bib0001","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103418_bib0049","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103418_bib0003","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103418_bib0037","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103418_bib0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.vaccine.2007.10.044","article-title":"Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates","volume":"26","author":"Jafarzadeh","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.msard.2021.103418_bib0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/BOR.0000000000000272","article-title":"Suppression of normal immune responses after treatment with rituximab","volume":"28","author":"Kado","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.msard.2021.103418_bib0060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/BOR.0000000000000377","article-title":"Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy","volume":"29","author":"Kado","year":"2017","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.msard.2021.103418_bib0026","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaip.2014.06.003","article-title":"Rituximab and immune deficiency: case series and review of the literature","volume":"2","author":"Kaplan","year":"2014","journal-title":"J Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.msard.2021.103418_bib0079","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/ene.12132","article-title":"Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab","volume":"20","author":"Kim","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.103418_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102466","article-title":"Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia","volume":"19","author":"Kridin","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2021.103418_bib0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000769","article-title":"Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases","volume":"7","author":"LaHue","year":"2020","journal-title":"Neurol .Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2021.103418_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153217","article-title":"Different risk of tuberculosis and efficacy of isoniazid prophylaxis in rheumatoid arthritis patients with biologic therapy: a nationwide retrospective cohort study in Taiwan","volume":"11","author":"Liao","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2021.103418_bib0089","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-021-01355-0","article-title":"Delayed production of neutralizing antibodies correlates with fatal COVID-19","volume":"27","author":"Lucas","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2021.103418_bib0045","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41582-020-0313-y","article-title":"Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations","volume":"16","author":"Mao-Draayer","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2021.103418_bib0011","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1212\/NXI.0000000000000498","article-title":"Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders","volume":"5","author":"Marcinn\u00f2","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103418_bib0048","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.msard.2019.01.044","article-title":"Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies","volume":"30","author":"Mayer","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103418_bib0053","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/art.40937","article-title":"Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases","volume":"71","author":"Md Yusof","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.msard.2021.103418_bib0039","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.4161\/hv.28350","article-title":"Polysaccharide-specific B cell responses to vaccination in humans","volume":"10","author":"Mitchell","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.msard.2021.103418_bib0071","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s10067-016-3313-y","article-title":"Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature","volume":"35","author":"Monaco","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.msard.2021.103418_bib0002","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103418_bib0035","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/ene.12130","article-title":"Hospital admission due to infections in multiple sclerosis patients","volume":"20","author":"Montgomery","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.103418_bib0040","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S1473-3099(19)30310-X","article-title":"Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial","volume":"19","author":"Mullane","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.msard.2021.103418_bib0080","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","article-title":"The effect of rituximab on vaccine responses in patients with immune thrombocytopenia","volume":"122","author":"Nazi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.msard.2021.103418_bib0074","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/14740338.2020.1807002","article-title":"Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review","volume":"19","author":"Ng","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.msard.2021.103418_bib0031","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0264-410X(01)00432-7","article-title":"A new accelerated vaccination schedule for rapid protection against hepatitis A and B","volume":"20","author":"Nothdurft","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.msard.2021.103418_bib0092","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000845","article-title":"Tailoring B cell depletion therapy in MS according to memory B cell monitoring","volume":"7","author":"Novi","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103418_bib0061","doi-asserted-by":"crossref","DOI":"10.1136\/bmjoq-2019-000770","article-title":"The development of a quality improvement project to improve infection prevention and management in patients with asplenia or hyposplenia","volume":"9","author":"O'Neill","year":"2020","journal-title":"BMJ Open Qual."},{"key":"10.1016\/j.msard.2021.103418_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102988","article-title":"Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases","volume":"52","author":"Oksbjerg","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103418_bib0072","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1212\/WNL.54.11.2147","article-title":"Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor","volume":"54","author":"Openshaw","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103418_bib0018","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-009-0806-7","article-title":"Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBs Ag-positive and HBs Ag-negative patients","volume":"89","author":"Pei","year":"2010","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.msard.2021.103418_bib0093","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1212\/NXI.0000000000000390","article-title":"Teriflunomide slows BVL in relapsing MS: a reanalysis of the TEMSO MRI data set using SIENA","volume":"4","author":"Radue","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103418_bib0009","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.msard.2021.103418_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108554","article-title":"Varicella zoster immunity loss in multiple sclerosis patient treated with ocrelizumab","volume":"223","author":"Rapisarda","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.msard.2021.103418_bib0017","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2468-1253(17)30045-6","article-title":"Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study","volume":"2","author":"Razavi","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.msard.2021.103418_bib0019","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American gastroenterological association institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.msard.2021.103418_bib0023","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/practneurol-2020-002527","article-title":"Protecting people with multiple sclerosis through vaccination","volume":"20","author":"Reyes","year":"2020","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.msard.2021.103418_bib0081","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s10067-020-05042-2","article-title":"Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study","volume":"39","author":"Richi","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.msard.2021.103418_bib0041","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/cncr.32700","article-title":"Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: a database study","volume":"126","author":"Rodriguez","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.msard.2021.103418_bib0062","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMcp1314291","article-title":"Care of the asplenic patient","volume":"371","author":"Rubin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103418_bib0029","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.anai.2018.03.017","article-title":"Hepatitis B vaccine nonresponders","volume":"121","author":"Saco","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.msard.2021.103418_bib0067","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000034","article-title":"Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the autoimmunity and rituximab registry","volume":"1","author":"Salmon","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.msard.2021.103418_bib0056","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis","volume":"78","author":"Salter","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103418_bib0032","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1476-0711-2-10","article-title":"Comparison of the accelerated and classic vaccination schedules against Hepatitis B: three-week Hepatitis B vaccination schedule provides immediate and protective immunity","volume":"2","author":"Salto\u011flu","year":"2003","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"10.1016\/j.msard.2021.103418_bib0005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40263-020-00704-w","article-title":"Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis","volume":"34","author":"Sellebjerg","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2021.103418_bib0066","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/1756-185X.13365","article-title":"Early onset neutropenia and thrombocytopenia following rituximab in lupus nephritis","volume":"22","author":"Shah","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.msard.2021.103418_bib0034","doi-asserted-by":"crossref","unstructured":"Simpson-Yap S., De B.E., Kalincik T., et\u00a0al. Associations of DMT therapies with COVID-19 severity in multiple sclerosis. medRxiv, https:\/\/medrxiv.org\/cgi\/content\/short\/2021.02.08.21251316 (2021).","DOI":"10.1101\/2021.02.08.21251316"},{"key":"10.1016\/j.msard.2021.103418_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102851","article-title":"Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment","volume":"50","author":"Smets","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103418_bib0044","doi-asserted-by":"crossref","first-page":"e734","DOI":"10.1212\/NXI.0000000000000734","article-title":"pregnancy","volume":"7","author":"Smith","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103418_bib0033","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103418_bib0090","article-title":"SARS-CoV-2 serology after COVID-19 in multiple sclerosis: an international cohort study","author":"Sormani","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103418_bib0059","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7861\/clinmedicine.16-6-571","article-title":"Secondary antibody deficiency-causes and approach to diagnosis","volume":"16","author":"Srivastava","year":"2016","journal-title":"Clin. Med."},{"key":"10.1016\/j.msard.2021.103418_bib0013","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","article-title":"Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation","volume":"265","author":"Tallantyre","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103418_bib0068","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/art.30427","article-title":"Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections","volume":"63","author":"Tesfa","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.msard.2021.103418_bib0073","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years","volume":"42","author":"Van Vollenhoven","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.msard.2021.103418_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102887","article-title":"B cell therapy and the use of RNA-based COVID-19 vaccines","author":"Vishnevetsky","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103418_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102454","article-title":"Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis","volume":"46","author":"Vollmer","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103418_bib0058","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann. Clin. Trans. Neurol."},{"key":"10.1016\/j.msard.2021.103418_bib0025","first-page":"5753","article-title":"Human papillomavirus vaccines: WHO position paper","volume":"35","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.msard.2021.103418_bib0036","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(20)30342-2","article-title":"Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Wolinsky","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2021.103418_bib0085","first-page":"e326","article-title":"P 2 effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFNb-1a\u2013controlled OPERA I and OPERA II studies","volume":"128","author":"Ziemssen","year":"2017","journal-title":"Clin. Neurophysiol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T16:36:58Z","timestamp":1735576618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821006842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":94,"alternative-id":["S2211034821006842"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103418","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Derisking CD20-therapies for long-term use","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103418"}}